Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations

Blood Cancer J. 2014 Dec 12;4(12):e266. doi: 10.1038/bcj.2014.87.

Authors

M J Kersten¹, W Kraan², J Doorduijn³, J Bromberg⁴, K Lam⁵, P M Kluin⁶, B J van der Holt⁷, M Spaargaren², S T Pals²

Affiliations

¹ Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
² Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
³ Department of Hematology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
⁴ Department of Neurology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
⁵ Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
⁶ Department of Pathology, University Medical Center, Groningen, The Netherlands.
⁷ HOVON Data Center, Erasmus MC Cancer Institute-Clinical Trial Center, Rotterdam, The Netherlands.

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Multicenter Study

MeSH terms

Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Brain Neoplasms / drug therapy
Brain Neoplasms / genetics*
Brain Neoplasms / pathology
CD79 Antigens / genetics*
Cisplatin / administration & dosage
Cytarabine / administration & dosage
Dexamethasone / administration & dosage
Female
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / genetics*
Lymphoma, Large B-Cell, Diffuse / pathology
Male
Methotrexate / administration & dosage
Middle Aged
Mutation*
Myeloid Differentiation Factor 88 / genetics*
Neoplasm Proteins / genetics*
Rituximab

Substances

Antibodies, Monoclonal, Murine-Derived
CD79 Antigens
CD79B protein, human
MYD88 protein, human
Myeloid Differentiation Factor 88
Neoplasm Proteins
Cytarabine
Rituximab
Dexamethasone
Cisplatin
Methotrexate